<?xml version="1.0" encoding="UTF-8" standalone="yes"?><ns0:RetrieveMultipleValueSetsResponse xmlns:ns0="urn:ihe:iti:svs:2008" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">    <ns0:DescribedValueSet ID="2.16.840.1.113883.3.7643.3.1009" displayName="Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue" version="N/A">        <ns0:ConceptList>            <ns0:Concept code="1657005" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="40 ML ipilimumab 5 MG/ML Injection"/>            <ns0:Concept code="1657012" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="10 ML ipilimumab 5 MG/ML Injection"/>            <ns0:Concept code="1657190" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="4 ML nivolumab 10 MG/ML Injection"/>            <ns0:Concept code="1657195" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="10 ML nivolumab 10 MG/ML Injection"/>            <ns0:Concept code="1657746" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="pembrolizumab 50 MG Injection"/>            <ns0:Concept code="1657750" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="4 ML pembrolizumab 25 MG/ML Injection"/>            <ns0:Concept code="1792780" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="20 ML atezolizumab 60 MG/ML Injection"/>            <ns0:Concept code="1875542" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="10 ML avelumab 20 MG/ML Injection"/>            <ns0:Concept code="1919507" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="2.4 ML durvalumab 50 MG/ML Injection"/>            <ns0:Concept code="1919515" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="10 ML durvalumab 50 MG/ML Injection"/>            <ns0:Concept code="1991412" codeSystem="2.16.840.1.113883.6.88" codeSystemName="RXNORM" codeSystemVersion="2019-10" displayName="24 ML nivolumab 10 MG/ML Injection"/>        </ns0:ConceptList>        <ns0:Source>Oncology Nursing Society </ns0:Source>        <ns0:Purpose>(Clinical Focus: This value set contains RxNORM concepts for various checkpoint inhibitor agents, regardless of dosage or administration route.),(Data Element Scope: Various drugs used in the treatment of cancer which may cause fatigue.),(Inclusion Criteria: atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab),(Exclusion Criteria: Brand name drugs and drug packs. Chemotherapy and biotherapy agents which may cause fatigue.)</ns0:Purpose>        <ns0:Definition>(2.16.840.1.113883.3.7643.2.1006:Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue)</ns0:Definition>        <ns0:Type>Grouping</ns0:Type>        <ns0:Binding>Dynamic</ns0:Binding>        <ns0:Status>Active</ns0:Status>        <ns0:RevisionDate>2019-01-08</ns0:RevisionDate>    </ns0:DescribedValueSet></ns0:RetrieveMultipleValueSetsResponse>